2026 Esther H. Chang: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	65	9128	8419	4053	3635	144	15628

Overview

Esther H. Chang is affiliated with Georgetown University Medical Center in the United States. Their research spans several interconnected areas within medicine, biochemistry, genetics, molecular biology, immunology, and microbiology. The scientist's work incorporates multiple subfields, including immunology, oncology, molecular biology, genetics, and biomedical engineering.

The main research topics addressed by Esther H. Chang include:

Cancer Immunotherapy and Biomarkers
Cancer Mechanisms and Therapy
Pesticide Exposure and Toxicity
Cholinesterase and Neurodegenerative Diseases
Immunotherapy and Immune Responses
Glioma Diagnosis and Treatment
Nanoplatforms for Cancer Theranostics

Recent publications provide insight into the range of research themes explored:

"TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19," 2022, Viruses
"A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models," 2022, Cells
"A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer," 2021, Journal of Clinical Oncology
"A Pralidoxime Nanocomplex Formulation Targeting Transferrin Receptors for Reactivation of Brain Acetylcholinesterase After Exposure of Mice to an Anticholinesterase Organophosphate," 2024, International Journal of Nanomedicine
"SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors," 2024, International Journal of Nanomedicine

Publication venues where Esther H. Chang has contributed include:

International Journal of Nanomedicine
Neuro-Oncology
Viruses
Cells
Journal of Clinical Oncology

Frequent co-authors collaborating with Esther H. Chang are:

Joe B. Harford
Sang Soo Kim
Kathleen F. Pirollo
Antonina Rait
Manish Moghe

Best Publications

Mechanism of activation of a human oncogene.

Clifford J. Tabin;Scott M. Bradley;Cornelia I. Bargmann;Robert A. Weinberg

1773
Citations
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.

Shiv Srivastava;Zhiqiang Zou;Kathleen Pirollo;William Blattner

1606
Citations
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus

Esther H. Chang;Esther H. Chang;Mark E. Furth;Edward M. Scolnick;Douglas R. Lowy

783
Citations
Does a targeting ligand influence nanoparticle tumor localization or uptake

Kathleen F. Pirollo;Esther H. Chang

484
Citations
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus.

R W Ellis;D DeFeo;J M Maryak;H A Young

462
Citations
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses.

Esther H. Chang;Matthew A. Gonda;Ronald W. Ellis;Edward M. Scolnick

373
Citations
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus

Deborah Defeo;Matthew A. Gonda;Howard A. Young;Esther H. Chang

366
Citations
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.

Liang Xu;Cheng-Cheng Huang;Weiqun Huang;Wen-Hua Tang

351
Citations
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

Neil Senzer;John Nemunaitis;John Nemunaitis;Derek Nemunaitis;Cynthia Bedell

293
Citations
Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies

Kathleen F. Pirollo;Esther H. Chang

292
Citations
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus.

A I Oliff;G L Hager;E H Chang;E M Scolnick

288
Citations
Transferrin- Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts

Liang Xu;Kathleen F. Pirollo;Wen-Hua Tang;Antonina Rait

280
Citations
Characterization of a human colon/lung carcinoma oncogene

Melissa S. McCoy;John J. Toole;James M. Cunningham;Esther H. Chang;Esther H. Chang

255
Citations
Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System

Kathleen F. Pirollo;Antonina Rait;Qi Zhou;Sung Hee Hwang

242
Citations
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.

Eric J. Kuhn;Eric J. Kuhn;Richard A. Kurnot;Richard A. Kurnot;Isabell A. Sesterhenn;Isabell A. Sesterhenn;Esther H. Chang;Esther H. Chang

226
Citations
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.

Kathleen F. Pirollo;Gerald Zon;Antonina Rait;Qi Zhou

200
Citations
The Mspl polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products

Tim McDaniel;David Carbone;Takashi Takahashi;Peter Chumakov

193
Citations
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.

Liang Xu;Wen-Hua Tang;Cheng-Cheng Huang;William Alexander

188
Citations
Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy.

L. Xu;K.F. Pirollo;E.H. Chang

187
Citations
p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy

Kathleen F Pirollo;Kathleen F Pirollo;Zhengmei Hao;Antonina Rait;Antonina Rait;Yng-Ju Jang

178
Citations